Last updated: 11/03/2018 19:30:37
Pfizer completed the acquisition of GSK's vaccine Nimenrix on 01-October-2015. The sponsorship for this clinical study was transferred from GSK to Pfizer as of 31-December-2016.The product that is studied in this clinical study, together with the rights to the data and results generated, has been transferred by GSK to Pfizer. GSK’s Clinical Study Register is no longer maintained for this study. The most up to date information is available on: www.clinicaltrials.gov. To request access to clinical study data from Pfizer, go here: http://www.pfizer.com/research/clinical_trials/trial_data_and_results

The long-term antibody persistence of GSK Biologicals’ MenACWY-TT vaccine (GSK134612) versus Mencevax ACWY in healthy adolescents and adults and booster response to MenACWY-TT vaccine administered at 10 years post-primary vaccination

GSK study ID
116725
Clinicaltrials.gov ID
NCT01934140
EudraCT ID
2012-005639-10
EU CT Number
Not applicable
Trial status
No longer a GSK study
No longer a GSK study
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: The long-term antibody persistence of GSK Biologicals’ MenACWY-TT vaccine (GSK134612) versus Mencevax ACWY in healthy adolescents and adults and booster response to MenACWY-TT vaccine administered at 10 years post-primary vaccination
Trial description: The purpose of this study is to evaluate the long-term antibody persistence from 6, 7, 8, 9 to 10 years post-administration of MenACWY-TT conjugate vaccine as compared to Mencevax ACWY when given to healthy subjects 11 to 55 years of age. In addition, the safety and immunogenicity of a booster dose of MenACWY-TT vaccine administered to all eligible subjects 10 years after the primary vaccination will be evaluated.
All Filipino subjects who received the primary vaccination in the primary vaccination study 107386 (NCT00356369) will be invited to enrol in the long-term follow up and booster phase. No new subjects will be enrolled.
Primary purpose:
Prevention
Trial design:
Parallel Assignment
Masking:
None (Open Label)
Allocation:
Randomized
Primary outcomes:

Immunogenicity with respect to the components of the investigational vaccine in terms of antibody titres

Timeframe: During the long-term follow-up phase (6, 7, 8, 9 and 10 years after primary vaccination in Study MENACWY-TT-015)

Secondary outcomes:

Immunogenicity with respect to the components of the investigational vaccine in terms of antibody titres and antibody concentration

Timeframe: One month post booster vaccination at ten years after primary vaccination

Occurrence of solicited local and general symptoms

Timeframe: Days 0-3 following the booster vaccination

Occurrence of unsolicited symptoms

Timeframe: Up to 31 days following booster vaccination

Occurrence of serious AEs, and new onset chronic illness(es) (e.g. autoimmune disorders, asthma, type 1 diabetes and allergies), GBS (Guillain-Barre Syndrome) and meningococcal disease

Timeframe: From administration of the vaccine dose until study end (Month 126)

Interventions:
  • Vaccine: Meningococcal vaccine GSK134612
    • Enrollment:
    309
    Primary completion date:
    2016-18-08
    Observational study model:
    Not applicable
    Time perspective:
    Not applicable
    Clinical publications:
    Not applicable
    Medical condition
    Infections, Meningococcal
    Product
    GSK134612A
    Collaborators
    Not applicable
    Study date(s)
    April 2014 to August 2016
    Type
    Interventional
    Phase
    3

    Participation criteria

    Sex
    Female & Male
    Age
    17Years - 66Years
    Accepts healthy volunteers
    Yes
    • All subjects must satisfy the following criteria at study entry to the persistence phase:
    • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol. Or /and subjects’ parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
    • Child in care.
    • Previous vaccination with meningococcal polysaccharide or conjugate vaccine outside of study MENACWY-TT-015.
    Inclusion and exclusion criteria
    Inclusion criteria:

      All subjects must satisfy the following criteria at study entry to the persistence phase:

      • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol. Or /and subjects’ parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
      • A male or female between and including 17 and 66 years of age at the time of entry into the present study.
      • Has completed the vaccination phase of the vaccination study MENACWY-TT-015.
      • In alignment with local laws and regulations, written informed consent obtained from parents/LAR(s) of the subject and written informed assent obtained from the subject if the subject is less than 18 years of age, or written informed consent obtained from the subject if the subject has achieved the 18th birthday. The subjects ≥18 years of age at the time of enrollment will sign the informed consent form, even if the parent/ LAR previously signed the ICF before the subject reached the legal age of consent.
      • Healthy subjects as established by medical history and history-directed physical examination before entering into the study. All subjects must satisfy the following additional criteria prior to entry of the booster phase:
      • Female subjects of non-childbearing potential may be enrolled in the study.

      Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause.

      • Female subjects of childbearing potential may be enrolled in the study, if the subject:
    • has practiced adequate contraception for 30 days prior to vaccination, and
    • has a negative pregnancy test on the day of vaccination, and
    • has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.
    Exclusion criteria:

      Child in care.

      • Previous vaccination with meningococcal polysaccharide or conjugate vaccine outside of study MENACWY-TT-015.
      • History of meningococcal disease due to serogroup A, C, W-135 or Y.
      • Any confirmed or suspected immunosuppressive or immunodeficient condition, including Human Immunodeficiency Virus (HIV) infection, based on medical history and physical examination.
      • Major congenital defects or serious chronic illness.
      • Family history of congenital or hereditary immunodeficiency.
      • History of chronic alcohol consumption and/or drug abuse. Additional exclusion criteria for booster phase at Month 120 study entry (to be checked at Month 120) for all subjects
      • Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the booster dose of study vaccine, or planned use during the follow-up period.
      • Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs within six months prior to the booster vaccine dose. Inhaled and topical steroids are allowed.
      • Administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the booster dose of study vaccine or planned administration within 30 days after vaccination (with the day of vaccination considered Day 0), with the exception of a licensed inactivated influenza vaccine.
      • Administration of immunoglobulins and/or any blood products within the three months preceding the booster vaccination or planned administration during the follow-up period.
      • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product.
      • Previous vaccination with tetanus toxoids within the last month.
      • History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines.
      • History of any neurological disorders or seizures, including Guillain-Barré syndrome (GBS). History of a simple, single febrile seizure is permitted.
      • Acute disease and/or fever at the time of enrollment.
    • Fever is defined as temperature ≥ 37.5°C for oral, axillary or tympanic route, or ≥ 38.0°C for rectal route. The preferred route for recording temperature in this study will be oral.

      • Subjects with a minor illness without fever may, be enrolled at the discretion of the investigator.

      • Pregnant or lactating female.
      • Female planning to become pregnant or planning to discontinue contraceptive precautions.

    Trial location(s)

    This study does not involve prospective enrollment of participants.

    Study documents

    No study documents available.

    Results overview

    Study Results yet to be posted

    Recruitment status
    No longer a GSK study
    Actual primary completion date
    2016-18-08
    Actual study completion date
    2016-18-08

    Plain language summaries

    Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

    Additional information about the trial

    Additional information
    Not applicable
    Participate in clinical trial
    Access to clinical trial data by researchers
    Visit website